135 results about "COPD" patented technology

A sensing device is used to determine the risk and / or probability of an COPD-attack and / or asthma attack of a patient. The sensing device includes a collection device for the non-invasive collection of a biological sample and a biosensor for determining the existence and / or the amount of a biomarker in the biological sample, preferably without the need for sample preparation. The device also includes a control and evaluation device that determines a risk and / or probability of an COPD and / or asthma-attack based on the existence and / or measured amount; and a measuring arrangement and a method for the maintenance of said sensing device or measurement arrangement, and an output unit that outputs the risk / probability.

The invention discloses an EIT-based respiratory muscle force and lung compliance closed-loop evaluation system, which is characterized by comprising a multi-frequency EIT injection / sampling unit, a signal processing unit and a signal processing unit, a pressure measurement and synchronization unit; an FPGA clock synchronization triggering unit; an EIT preprocessing unit; a compressed sensing reconstruction unit; a [delta] Z-Pressure fitting unit is adopted; a feature extraction unit; a control decision unit; and the self-adaptive NMES participates in a trend recording unit. According to the method, advanced technologies such as multi-frequency EIT, compressed sensing reconstruction, machine learning fitting, fuzzy + PID mixed control and federated learning are integrated, a new normal form for closed-loop evaluation and optimization of respiratory muscle force and lung compliance is created, and the method has great clinical value for rehabilitation of diseases such as COPD and neuromuscular respiratory failure.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape as the devices are deployed into the tissue. This action causes the pulmonary treatment devices to corkscrew into damaged tissue, becoming sufficiently entwined to allow pulling of the tissue by retraction of the device. This in turn re-tensions the lung causing lung volume reduction.

A respiratory mask or other sealing interface can be used in combination with a nasal cannula or other unsealing interface in providing respiratory therapies for the treatment of COPD or OSA. The mask can act as a pressure vessel over the top of a nasal cannula, with the intention of increasing expiratory pressure whilst allowing the nasal cannula to provide a user with breathing gases of a high humidity and temperature. The ability to selectively apply increased expiratory pressure may be effective in reducing a user's breathing rate and thus beneficial in the treatment of respiratory distress.

The invention belongs to the field of medical image analysis and artificial intelligence, and provides a COPD early screening method and application based on a dynamic dependency graph and self-supervised learning for the problems of insufficient sensitivity, insufficient feature representation and the like in the prior art, and the method comprises the steps: S1, preprocessing chest CT image data, and obtaining an enhanced image block; s2, generating an image block sequence of the enhanced image blocks; s3, inputting the image block sequence into a self-supervised learning Transformer encoder, and constructing a total loss function of self-supervised learning; and S4, determining a model for predicting the COPD risk probability, and constructing a loss function with a supervised classification task to optimize the model of the COPD risk probability. And S5, constructing a comprehensive loss function, and integrally optimizing the model for predicting the COPD risk probability. According to the method, multiple advanced technologies are fused, and early detection and risk assessment are carried out on COPD in an automatic, efficient and high-precision mode.

The invention relates to the technical field of medical care information processing, and particularly discloses a pulmonary nodule risk prediction system and method for a patient with chronic obstructive pulmonary disease, and the system comprises a historical examination data acquisition module which collects multiple CT examination data, lung function data and lung quantitative data of the patient with chronic obstructive pulmonary disease; the growth inflection point recognition module recognizes a pulmonary nodule growth inflection point of the patient; the risk prediction model building module builds a pulmonary nodule risk prediction model; the current patient risk prediction module inputs the current CT examination data, the current lung function data and the current lung quantitative data of the to-be-detected patient into the pulmonary nodule risk prediction model to obtain a current pulmonary nodule risk prediction result of the to-be-detected patient; the review time recommendation module obtains review recommendation time of the patient to be detected based on the current pulmonary nodule risk prediction result of the patient to be detected and a preset review time recommendation model, effective prediction of the pulmonary nodule risk of the patient with chronic obstructive pulmonary disease is achieved, and an important basis is provided for early diagnosis and treatment.

The invention provides an application of a polypeptide Nod-T3 in preparation of a medicine for treating lung diseases, the polypeptide Nod-T3 is derived from human protein, has the effect of remarkably inhibiting chronic lung inflammation and fibrosis caused by smoking, can be used for treating COPD and other smoking-related lung diseases, and is high in biocompatibility, small in toxicity, low in cost and suitable for clinical application. The polypeptide has the potential and development value of becoming a novel polypeptide drug.

The invention discloses an intelligent respiratory disease detection system based on lung function measurement indexes, and relates to the technical field of intelligent medical detection. The problems that diagnosis standards are not uniform and depend on experience, primary doctors are prone to missed diagnosis or misdiagnosis due to insufficient experience, and the efficiency of the detection process is low are solved. According to the method, a machine learning model is constructed based on lung function indexes, parameters are optimized through five-fold cross validation, automatic classification of asthma, COPD and ILD / DPLD is achieved, the overall diagnosis accuracy rate reaches 81.3%, the limitation that traditional diagnosis depends on doctor experience is broken through, and the basic medical diagnosis capacity is especially improved. Healthy people are rapidly eliminated through the FVC / FEV1 ratio, invalid calculation is reduced, meanwhile, multi-model weighted fusion is adopted for complex cases, diagnosis robustness is improved, it is ensured that diagnosis results conform to medical logic, the recognition degree of doctors is enhanced, a data basis is provided for clinical research and curative effect tracking, and respiratory disease diagnosis is promoted to develop towards the direction of automation and precision.

The invention relates to a class of small molecule inhibitors of GPR68 / OGR1, a proton-sensing / stretch-sensing / sheer-stress-sending G-protein coupled receptor, and related receptors GPR4 and GPR65. These inhibitors are useful as a therapeutic for glioblastoma and other neoplasms, as a monotherapy or adjuvant, and also can be used as a treatment for other conditions, such as osteoporosis, inflammatory bowel disease, autoimmune and chronic inflammatory diseases such as multiple sclerosis and inflammatory pain syndromes, GERD, aspiration pneumonitis, bacterial and viral pneumonia, COPD, acute respiratory distress syndrome (ARDS), and COVID-19.

The invention relates to the technical field of biological medicine, in particular to a drug screening model construction method based on airway organs, a model and application. The construction method of the drug screening model of the airway organoid comprises the steps of obtaining 2D airway epithelial cells, culturing the airway organoid, establishing an airway organoid inflammation model and / or establishing an airway organoid mucus secretion / goblet cell metaplasia model. Wherein the model is established according to the culture mode of the airway organ in cooperation with a specific stimulant for proliferation and differentiation. Compared with a traditional animal model, the organ-like model is low in cost and short in construction period, can better simulate the pathological process, can realize airway organ-like culture and establishment of an inflammation model and a mucus secretion / goblet cell metaplasia model at the same time, and has a good application prospect in drug detection of asthma and COPD diseases.

The invention discloses a construction method and application of a human-derived far-end airway organ-like COPD model, the constructed human-derived far-end airway organ-like COPD model is highly similar to COPD far-end airway tissue on the transcriptional level, and the pathological characteristics of COPD are well restored on the protein expression level and cilia function level. Therefore, the human-derived far-end airway organ-like COPD model constructed in vitro can simulate the COPD lesion of the far-end airway, and an available model is provided for researching the COPD pathological mechanism of the far-end airway. In addition, the requirements on time, temperature and quality inspection indexes of CSE extraction in operation are clear, and the batch-to-batch extraction quality and experiment repeatability of CSE can be well ensured. The cilia function is used as a detection index, the improvement effect of the medicine on the lung function can be better reflected, and data support of the function level can be provided for COPD medicine research.

A therapeutic genetic construct for addressing alpha-1 antitrypsin deficiency (AATD) and associated disorders. The genetic construct encodes: (a) a first pre-miRNA; (b) a second pre-miRNA; and (c) a transgene encoding AAT(M). The pre-miRNAs inhibit the expression of alleles encoding mutant variants of AAT, such as AAT(Z), AAT(S), AAT(I), AAT(Siiyama), and AAT(Mmalton). The construct may further comprise a liver-specific promoter. A vector, such as a gorilla adenoviral vector, comprising the genetic construct. A method of treating a disease or disorder, such as COPD, bronchiectasis, neonatal cholestasis, cirrhosis, fibrosis, and hepatocellular carcinoma, comprising administering a therapeutically effective amount of the aforementioned vector. A use of the genetic construct in the manufacture of a medicament for use in treating a disease or disorder. A composition comprising the genetic construct. A kit comprising the genetic construct.

A self-regulating oxygen delivery system (100) for COPD, comprising: an oxygen source designed to provide medical oxygen; a sensor module configured to record physiological parameters such as oxygen saturation (SpO2), respiratory rate and pulse rate; a microcontroller-based control unit that is functionally connected to the sensor module and the oxygen source; and an intelligent flow control mechanism controlled by the microcontroller, the system automatically adjusts the oxygen flow in real time based on the recorded physiological parameters to maintain optimal oxygen saturation levels.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

To provide methods for treating or preventing COPD and related conditions.SOLUTION: A disclosed method comprises a step of administering a therapeutic composition comprising an interleukin-33 (IL-33) such as an anti-IL-33 antibody or antigen binding fragment thereof to a subject in need thereof.SELECTED DRAWING: None

The utility model discloses a device for constructing a COPD fruit fly model by adopting smoke exposure, which is characterized in that a sealing mechanism is arranged between a box body and a box cover, the box body is transparent, a fruit fly placing mechanism is arranged in the box body, a smoke inlet pipe is arranged on the side wall of the box body in a penetrating manner, and a smoke pushing mechanism is arranged on the smoke inlet pipe; one end of a connecting pipe of the cigarette pushing mechanism is communicated with a cigarette pushing barrel, the other end of the connecting pipe is provided with a double-layer sleeve body, the double-layer sleeve body comprises an outer sleeve body and an inner sleeve arranged in the outer sleeve body, the outer sleeve body and the inner sleeve are arranged on the periphery and the inner wall of a cigarette inlet pipe in a sleeved mode respectively, the outer sleeve body is connected with the outer wall of the connecting pipe, and the inner sleeve is communicated with the connecting pipe. The smoke pushing cylinder comprises a needle cylinder and a piston arranged in the needle cylinder in a penetrating mode. According to the smoke exposure device, smoke can enter the smoke box through the smoke inlet conveniently for smoke exposure, the smoke exposure device can be used for construction of a COPD disease model, drug treatment and drug effect evaluation, and technical support is provided for construction of the COPD model in a smoke exposure mode.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

The invention discloses a chronic obstructive pulmonary lung region segmentation system based on computer vision, and relates to the technical field of medical image processing, an image data acquisition module is utilized to acquire an original lung CT image of a patient, and an input module is utilized to acquire the original lung CT image of the patient according to each preset pixel region of the lung. And calculating and outputting a gray value Hi of an ith pixel point by utilizing a segmentation processing module, judging an ith pixel point segmentation result FGi of each pixel region, then collecting all the ith pixel point segmentation results FGi, carrying out expansion corrosion processing, then calculating a final segmentation result FGJ, and displaying a final segmentation optimization result on a display module according to the final segmentation result FGJ. According to the method, the segmentation precision is improved, the anti-noise capability is enhanced, adaptive segmentation is realized, and the system has important clinical significance and practical application value in early diagnosis and treatment of chronic obstructive pulmonary disease due to the beneficial effects.

The invention discloses an intelligent early warning system for acute exacerbation of COPD home NPPV, which belongs to the technical field of medical treatment and comprises a real-time multi-dimensional physiological data time sequence acquisition module, a COPD acute exacerbation prediction model and an early warning module. The real-time multi-dimensional physiological data time sequence acquisition module is used for acquiring a real-time multi-dimensional physiological data time sequence of a patient; the COPD acute exacerbation prediction model is used for outputting the probability that the patient has COPD acute exacerbation in the future according to the input real-time multi-dimensional physiological data time sequence; and the early warning module is used for performing early warning when the probability of acute exacerbation of COPD of the patient in the future is greater than a preset threshold value. According to the method, the prediction precision of whether COPD acute exacerbation occurs in the future can be improved, and early discovery and early treatment are realized.

Active auscultation can be used to determine the characteristics of a user's organs (e.g., lungs or heart). An acoustic or piezoelectric signal (e.g., pulses, tones, and / or broadband pulses) can be projected onto the body or chest of an animal (typically a human). The signal interacts with the body or lungs and, in some cases, may cause resonance within the body / lungs. The resulting signal can be emitted from the body and analyzed to determine, for example, the resonant frequency of the lungs and / or how the sound is absorbed, reflected, or modified by the body. This information can indicate lung characteristics such as lung capacity, the amount of air trapped in the lungs, and / or the presence of COPD.

The invention belongs to the technical field of medicines, and relates to an aromatic ring thiazine derivative, in particular to structural forms such as free alkali, isomeride and pharmaceutically acceptable salt form of the compound. Methods for preparing such compounds; compositions comprising such compounds and therapeutic uses thereof. Based on a histamine PI3K delta receptor ligand, a series of compounds with novel structures are developed, a series of related biological tests are carried out on the compounds, and test results show that the compounds find novel PI3K delta high-selectivity inhibitors, have the characteristics of small toxic and side effects and low bioavailability, and have broad application prospects. The pharmaceutical composition is used for developing inhaled medicines suitable for treating respiratory system diseases such as asthma and COPD, and has important clinical significance and social value.

The present invention generally relates to pharmaceutical composition comprising a LABA agent, optionally in combination with other active ingredients, a mixture of an acid and a chelating agent, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.

The present invention relates to novel 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as potent inhibitors of transforming growth factor-beta receptor I (also known as activin receptor-like kinase 5) (TGFβRI) / ALK5. Other objects of the present invention are to provide processes for preparing these compounds; pharmaceutical compositions comprising an effective amount of these compounds; the use of said compounds for the preparation of a medicament for the treatment of pathological conditions or diseases which can be ameliorated by the inhibition of transforming growth factor-beta receptor I (TGFβRI) / ALK5, such as respiratory diseases, including idiopathic pulmonary fibrosis, asthma, COPD and lung cancer and skin and ocular fibrotic disorders.

The invention relates to the technical field of medical image processing, and discloses a chronic obstructive pulmonary emphysema distribution quantitative method and system based on multi-scale segmentation, and the method comprises the steps: carrying out the anisotropic diffusion filtering noise reduction of a chest CT image; segmenting a lung field and removing a blood vessel bronchial structure by adopting a region growing algorithm; multi-scale image representation is constructed based on a Gaussian pyramid, an emphysema candidate area is identified in a coarse scale layer, and a boundary is accurately drawn by adopting a self-adaptive threshold value in a fine scale layer; extracting local texture features to distinguish the lobular central emphysema and the total lobular emphysema; dividing severity levels according to spatial aggregation characteristics and density gradient distribution, and calculating an air swelling volume ratio and a distribution heterogeneity index; the three-dimensional pseudo-color volume is used for drawing visualization, a structured quantitative report is generated, accurate segmentation and subtype classification of the emphysema area are achieved, and comprehensive quantitative analysis indexes are provided.

This invention relates to catheter and handle assemblies for tissue treatment. More specifically, the invention relates to a catheter assembly having an elongated shaft, an ablation component coupled to one end of the shaft, and a handle coupled to the other end of the shaft. The handle facilitates axial and circumferential positioning of the ablation component via the shaft in an airway, tubing, or blood vessel for tissue treatment. Embodiments include using the handle during treatment of lung diseases such as COPD and asthma to facilitate axial and circumferential positioning of the shaft and ablation component through and independently of the working channel of a bronchoscope.

The present invention relates to the technical field of heterocyclic compound drugs and their preparation and application, and specifically to a tropane alkaloid composition for the treatment of COPD and its application. The composition combines tropane alkaloids, mannose-6-phosphate and polylactic acid-glycolic acid copolymer, and is constructed into a nanocomposite by nanoparticle preparation technology for aerosol inhalation administration. The composition aims to solve the problems of low bioavailability and lack of targeting in conventional administration of tropane alkaloids. Targeted delivery is achieved by introducing mannose-6-phosphate into the surface of nanoparticles, promoting drug enrichment in the lungs, and using polylactic acid-glycolic acid copolymer to control drug release, thereby increasing local drug concentration and therapeutic efficacy in the lungs.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of invertible pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape. In these embodiments, a portion of the device is invertible. Thus, each device is able to store energy at least in the inversion, wherein the energy is utilized to continually tension the lung as the device relaxes toward its original shape.

The present invention relates to compounds that are cyclic carbamate and ureas benzo-morpholine and benzo-thiomorpholine derivatives of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.